AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2018--
Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy
company developing a new approach to treating cancer based upon a novel
proprietary technology platform, announced today the appointment of Jan
Stevens, RN, as the Company’s Vice President of Clinical Operations. In
this role, Ms. Stevens joins the Cambridge office to contribute in
supporting various clinical development programs for the Company’s
immunogene therapy, Oncoprex™, which is currently being evaluated in
clinical and preclinical studies at MD Anderson Cancer Center for the
treatment of non-small cell lung cancer (NSCLC).
Ms. Stevens has served as a clinical consultant to Genprex since June
2018. In her new role, Ms. Stevens will lead clinical operations and
support corporate development efforts, focusing on expanding research
and clinical development opportunities, including the expansion of
Genprex’s Oncoprex + Tarceva combination trial across multiple US sites.
“I am excited to join the Genprex team and work with various
stakeholders to expand the clinical development program for Oncoprex,”
said Ms. Stevens. “In addition to continuing the Phase I/II trial with
Oncoprex in combination with Tarceva for NSCLC, we are working to
advance additional combination treatments into human studies, such as
Oncoprex plus checkpoint inhibitors.”
“We are pleased that Jan is joining our growing team in Cambridge, and
believe that she will bring her broad experience in managing the
clinical operations for our Oncoprex program,” said Julien L. Pham, MD,
MPH, President and Chief Operating Officer of Genprex.
Ms. Stevens brings nearly 20 years of comprehensive clinical operations
experience in the biopharma industry, with last the 10 years in a
leadership role as a Vice President Clinical Operations, working at
early to late stage oncology companies. Prior to joining Genprex, she
served on senior management teams at BERG, LLC and ZIOPHARM Oncology,
Inc., where she developed successful clinical strategies to advance
small molecules and biologics from first-in-man studies to global
pivotal trials. Prior to her work in clinical research, Ms. Stevens was
an acute care nurse in the Neurology Unit at Massachusetts General
Hospital. She received her RN degree with clinical affiliations from
Massachusetts General Hospital, Brigham and Women’s Hospital, and Beth
Israel Deaconess Hospital, and holds a Bachelor of Liberal Arts with
concentration in Ethics, cum laude, from Harvard University.
Read more about Genprex’s Oncoprex immunogene therapy platform here.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing a new
approach to treating cancer, based upon a novel proprietary technology
platform, including Genprex’s initial product candidate, Oncoprex™
immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s
platform technologies are designed to administer cancer-fighting genes
by encapsulating them into nanoscale hollow spheres called nanovesicles,
which are then administered intravenously and taken up by tumor cells
where they express proteins that are missing or found in low quantities.
Oncoprex™ has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed cell
death, in cancer cells, and modulates the immune response against cancer
cells. Oncoprex™ has also been shown to block mechanisms that create
For more information, please visit www.genprex.com or www.facebook.com/genprexinc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005379/en/
Source: Genprex, Inc.
James Heins, 203-682-8251